Aggressive regional surgery for advanced ovarian carcinoma

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Ovarian cystadenocarcinoma presents significant treatment challenges, particularly in advanced stages (Stage III and IV).
• Maximal cytoreduction through surgery is a critical component in managing advanced ovarian cancers.
• The timing of cytoreductive surgery in relation to adjuvant therapies remains an area for investigation.

Purpose of the Study:

• To evaluate the impact of the timing of regional surgery (RS) on survival outcomes in patients with advanced ovarian cystadenocarcinoma.
• To compare absolute survival (AS) and survival after RS (RSS) based on whether RS was performed at first-look, second-look, or third-look surgery.
• To assess the role of adjuvant chemotherapy and radiotherapy in conjunction with RS.

Main Methods:

• A nonrandomized study of 18 Stage III and 3 Stage IV ovarian cystadenocarcinoma patients treated between 1975 and 1983.
• Patients were divided into three groups based on the timing of RS: Group A (first-look), Group B (second-look), and Group C (third-look).
• Adjuvant chemotherapy regimens varied, with some Group C patients also receiving radiotherapy before RS. RS involved extensive tumor debulking procedures.

Main Results:

• No operative mortality was observed; overall postoperative morbidity was 33.3% due to wound sepsis.
• Group A demonstrated a 112-month survival probability of 0.52 (6/9 patients alive).
• Median survival times (AS and RSS) were significantly longer in Group A compared to Groups B and C, with RSS showing statistical significance (P < 0.05).

Conclusions:

• Performing regional surgery at first-look surgery, combined with adjuvant chemotherapy, appears to improve survival outcomes in advanced ovarian cystadenocarcinoma.
• While overall survival did not differ significantly between groups, survival after regional surgery was markedly better when performed earlier.
• The timing of maximal cytoreduction is a crucial factor in the management of advanced ovarian cancer.